MERIT Act
USA118th CongressHR-133| House
| Updated: 12/19/2024
Vern Buchanan
Republican Representative
Florida
Cosponsors (6)
Ways and Means Committee, Health Subcommittee, Health Subcommittee, Communications and Technology Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Mandating Exclusive Review of Individual Treatments (MERIT) Act This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held
Committee Consideration and Mark-up Session Held
Ordered to be Reported (Amended) by the Yeas and Nays: 42 - 0.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-764, Part I.
House Committee on Ways and Means Granted an extension for further consideration ending not later than Dec. 19, 2024.
Referred to the Subcommittee on Health.
Placed on the Union Calendar, Calendar No. 779.
Committee on Ways and Means discharged.
Health
Medical researchMedicarePrescription drugs
MERIT Act
USA118th CongressHR-133| House
| Updated: 12/19/2024
Mandating Exclusive Review of Individual Treatments (MERIT) Act This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held
Committee Consideration and Mark-up Session Held
Ordered to be Reported (Amended) by the Yeas and Nays: 42 - 0.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-764, Part I.
House Committee on Ways and Means Granted an extension for further consideration ending not later than Dec. 19, 2024.
Referred to the Subcommittee on Health.
Placed on the Union Calendar, Calendar No. 779.
Committee on Ways and Means discharged.
Vern Buchanan
Republican Representative
Florida
Cosponsors (6)
Ways and Means Committee, Health Subcommittee, Health Subcommittee, Communications and Technology Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Medical researchMedicarePrescription drugs